| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8667369 | Journal of the American Society of Echocardiography | 2018 | 7 Pages |
Abstract
GLS is a strong predictor of survival in patients with AL amyloidosis undergoing HCT, potentially providing incremental value over serum cardiac biomarkers for risk stratification. GLS should be considered as a standard parameter along with serum cardiac biomarkers when evaluating eligibility for HCT or other investigational therapies.
Keywords
HCTGLSBNPLVEFN-Terminal Pro–Brain Natriuretic PeptideNT-proBNPAL amyloidosisTnILeft ventricularSurvivaloverall survivalTroponin Itwo-dimensionallight chainGlobal longitudinal strainbrain natriuretic peptideAutologous hematopoietic cell transplantationHematopoietic cell transplantationleft ventricular ejection fraction
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Shawn C. MD, Heather J. MD, Elyn R. MA, Jonathan DO, Anthony F. MD, Hani MD, Carol L. MD, Richard M. MD, Jennifer E. MD,